31309-08-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-nitronicotinonitrile is used as a key intermediate in the synthesis of various pharmaceuticals. Its presence in the molecular structure of target drugs contributes to their therapeutic properties, such as antimicrobial, anti-inflammatory, or analgesic effects. 2-CHLORO-5-NITRONICOTINONITRILE's reactivity allows for the development of new drugs with improved efficacy and reduced side effects.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Chloro-5-nitronicotinonitrile is utilized in the manufacturing of pesticides and herbicides. Its incorporation into these products enhances their effectiveness in controlling pests and weeds, thereby improving crop yields and ensuring food security. 2-CHLORO-5-NITRONICOTINONITRILE's ability to form stable derivatives makes it suitable for use in long-lasting and environmentally friendly agrochemical formulations.
Used in Organic Synthesis:
2-Chloro-5-nitronicotinonitrile is used as a starting material in the synthesis of various organic compounds with nitrogen-containing functional groups. Its versatility allows for the preparation of a wide range of nitrogen-based compounds, such as amines, amides, and nitriles, which find applications in various industries, including pharmaceuticals, materials science, and chemical manufacturing.
Used in Research and Development:
In the field of research and development, 2-Chloro-5-nitronicotinonitrile serves as a valuable compound for exploring new chemical reactions and synthetic pathways. Its unique reactivity and structural features make it an ideal candidate for studying reaction mechanisms, developing new catalysts, and designing innovative synthetic strategies.

InChI:InChI=1/C6H2ClN3O2/c7-6-4(2-8)1-5(3-9-6)10(11)12/h1,3H

Upstream product

• 31309-38-3 2-hydroxy-5-nitronicotinonitrile 
• 20577-27-9 2-hydroxy-3-cyanopyridine 
• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 941083-49-4 C₆H₅N₃O₄ 
• 10128-92-4 2-hydroxynicotinamide 
• 60524-15-4 2-chloro-5-nitronicotinamide 
• 135795-55-0 2-chloro-3-chlorocarbonyl-5-nitropyridine 

Downstream Products

• 293735-69-0 5-nitro-2-(N-phenylaminocarbonylmethylthio)-3-cyanopyridine 
• 180424-13-9 2-[(β-hydroxyethyl)amino]-3-cyano-5-nitropyridine 
• 180424-17-3 2-[(di-β-hydroxyethyl)amino]-3-cyano-5-nitropyridine 
• 52505-43-8 2-ethoxycarbonyl-3-amino-5-nitrothieno[2,3-b]pyridine 
• 13600-46-9 5-amino-2-chloro-3-pyridinecarbonitrile 
• 6854-07-5 2-hydroxy-5-nitropyridine-3-carboxylic acid 
• 5418-51-9 5-nitro-2-hydroxypyridine 
• 208454-27-7 2-phenyloxy-3-cyano-5-nitropyridine 
• 293735-70-3 3-amino-5-nitro-2-(N-phenylaminocarbonyl)thieno[2,3-b]pyridine 
• 293735-80-5 8-nitro-3-phenylpyrido[3',2':4,5]thieno[3.2-d]pyrimidin-4(3H)-one 

Relevant academic research and scientific papers

PYRIDYL COMPOUND SUITABLE FOR THE TREATMENT OF METABOLIC DISORDERS

The description relates to a pyridyl compound of Formula 1 wherein A, B, X, R1, R2, R3, R4, R5, R6, and n are as defined in the specification, in all their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, their pharmaceutically acceptable salts, N-oxides, pharmaceutically acceptable solvates, isosteres and prodrugs thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. The description also relates to a process for the manufacture of the pyridyl compound and a pharmaceutical composition containing the pyridyl compound.

New 2-Thiopyridines as potential candidates for killing both actively growing and dormant mycobacterium tuberculosis cells

From in vivo observations, a majority of M. tuberculosis cells in latently infected individuals are in a dormant and probably nonculturable state, display little metabolic activity, and are phenotypically resistant to antibiotics. Despite many attempts, no specific antimicrobials effective against latent tuberculosis have yet been found, partly because of a lack of reliable and adequate in vitro models for screening of drug candidates. We propose here a novel in vitro model of M. tuberculosis dormancy that meets the important criteria of latency, namely, nonculturability of cells, considerable reduction of metabolic activity, and significant phenotypic resistance to the first-line antibiotics rifampin and isoniazid. Using this model, we found a new group of 2-thiopyridine derivatives that had potent antibacterial activity against both actively growing and dormant M. tuberculosis cells. By means of the model of M. tuberculosis nonculturability, several new 2-thiopyridine derivatives were found to have potent antitubercular activity. The compounds are effective against both active and dormant M. tuberculosis cells. The bactericidal effects of compounds against dormant M. tuberculosis was confirmed by using three different in vitro models of tuberculosis dormancy. The model of nonculturability could be used as a reliable tool for screening drug candidates, and 2-thiopyridine derivatives may be regarded as prominent compounds for further development of new drugs for curing latent M. tuberculosis infection.